These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Protease inhibitor new math.
    Author: Gilden D.
    Journal: GMHC Treat Issues; 1996 May; 10(5):3-6. PubMed ID: 11363583.
    Abstract:
    A clinical review is presented of the three most recently approved protease inhibitors for commercial use: ritonavir (Norvir), indinavir (Crixivan), and saquinavir (Invirase). Commercial developments are highlighted, revealing such problems as supply difficulties with indinavir, pricing controversies, and the negative drug interactions inherent in ritonavir. Also highlighted are the new protease inhibitors, ABT-378 and nelfinavir. A chart, some of which is theoretical, describing how ritonavir affects the body's processing of concurrent medication is provided.
    [Abstract] [Full Text] [Related] [New Search]